ID   B16VDXR
AC   CVCL_F937
SY   B16VDxR
DR   CLO; CLO_0001796
DR   CLDB; cl342
DR   Wikidata; Q54752531
RX   PubMed=3730255;
RX   PubMed=3741758;
CC   Doubling time: 25 +- 1.75 hours (PubMed=3730255).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_1950 ! B16V
SX   Male
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 12
//
RX   PubMed=3730255; DOI=10.1038/bjc.1986.149;
RA   Supino R., Prosperi E., Formelli F., Mariani M., Parmiani G.;
RT   "Characterization of a doxorubicin-resistant murine melanoma line:
RT   studies on cross-resistance and its circumvention.";
RL   Br. J. Cancer 54:33-42(1986).
//
RX   PubMed=3741758; DOI=10.1038/bjc.1986.166;
RA   Formelli F., Rossi C., Supino R., Parmiani G.;
RT   "In vivo characterization of a doxorubicin resistant B16 melanoma cell
RT   line.";
RL   Br. J. Cancer 54:223-233(1986).
//